Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -1.3% 76.00 75.50 78.00 78.00 71.00 78.00 416,167 16:46:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.9 5.5 0.8 93.8 346

Ekf Diagnostics Share Discussion Threads

Showing 2701 to 2723 of 3050 messages
Chat Pages: Latest  110  109  108  107  106  105  104  103  102  101  100  99  Older
DateSubjectAuthorDiscuss
26/11/2020
07:56
My understanding is that unless it's 100% accurate it can only be deemed as semi quantitative.
hastings
26/11/2020
07:53
Wan do you have any insight as to why the FDA seem to only have authorised it as semi-quantitative?
charlieej
26/11/2020
07:32
The highlighting of Kantaro's EUA for a semi-quantitative antibody test is interesting. I also note that in the UK and Europe (according to the release) the antibody test is categorised/authorised as quantitative. It will thus be interesting to see if the market remains underwhelmed. The strong institutional demand for EKF's Renalytix holding is encouraging for both Renalytix and indeed EKF. Whilst we await the next Renalytix/Verici!
wan
26/11/2020
07:32
The sale has resulted in gross proceeds of GBP7.705m to EKF and generated a profit of over GBP5.6m after dealing expenses. That's a chunk of money. AIMHO GLA BTG
btgman
26/11/2020
07:11
Great to see confirmation this morning of Kantaro's antibody test FDA approval. The market might get somewhat excited about this once the realisation sinks in that EKF have exclusive rights to market and distribute it "in the UK and Germany and non-exclusive rights in Europe". And also we have news that EKF are £7.7m better off after selling shares in Renalytix - and still hold another £4.6m's worth. Proof of the value EKF can generate from very little to start with.
rivaldo
25/11/2020
18:47
I should have added to the above that Renalytix is entitled to 10% of the proceeds from antibody tests, with revenues slated in for both 2021 and 2020. As I alluded to above though, I think that EKF's commercial arrangement is based on/enables healthy margins.
wan
25/11/2020
18:17
From the November Trading Update - A significantly improved trading in the core business in the final quarter, along with continued orders for the PrimeStore MTM COVID-19 sample collection device underpins the Board’s confidence of a strong full year performance. (END) Given that antibody testing is not part of the core business (and was only announced 28th October), and with PrimeStore separated out for specific mention, it is unlikely in my view, that the reference to "expected orders for the remainder of the year", contained anything for Kantaro antibody test orders. I had been monitoring recent Bio-Techne commentary (amongst others and other related things), hence my previous comments on here regarding the antibody test. The market may be underestimating the revenues from antibody testing, as up until now interest in and use of some of the competitors EUA antibody tests (the accuracy of which has been called into question) has be relatively low to non-existent. Perhaps why the market is not expecting much from EKF in this regard? So, it looks as though there is currently only two players in the market with an 'effective' antibody test offering, and one of those is Kantaro! Previous commentary from Bio-Techne implied that the margin for distributers/end users look set to be very healthy, particularly in the US. But until we hear something further from EKF, I am inclined to not say a lot more on the subject!
wan
25/11/2020
17:24
The FDA EUA announcement today is clearly positive news, but we do not know how much of the product that Bio-Techne manufactures is going to be allocated to the UK/European markets and so available for marketing and distribution (and so revenue generation) by EKF. We also do not know the commercial deal under the agreement between EKF and Kantaro. My assumption is that most of the kits now being produced will be targeted at the US market. As far as I am aware, Bio-Techne are the sole manufacturer of the test kits. If the Kantaro/EKF marketing and distribution agreement generates material revenues for EKF, it will issue an RNS, sooner or later. So, I can see why the Renalytix share price spiked today (after being subdued), but also why it had no immediate impact on the EKF share price, given its relatively small holding in Renalytix. Some of the other developments hold more immediate promise, in my view, PrimeStore products being an obvious example.
james188
25/11/2020
13:54
So, given the commentary from Bio-Techne stating that "manufacturing will begin with a capacity of 10 million tests per month", does that mean availability here and in Europe was limited/not available i.e. manufacturing at scale commences with FDA EUA?
wan
25/11/2020
13:37
Well the market seems to like the fact Kantaro received FDA EUA today for the antibody test in the US, with Renalytix share price responding positively to the news. (albeit I notice it's for a semi-quantitative test) hTTps://kantarobio.com/kantaro-receives-fda-emergency-use-authorization-for-semi-quantitative-covid-19-antibody-test-kit-that-detects-the-presence-and-level-of-sars-cov-2-igg-antibodies/
wan
25/11/2020
11:47
If we close below 59 today that would be the first close below the 52 dma since 1 April 2020. A strong performance South of that on renewed volumes will very much likely have v important ramifications on institutional money as this is the end of the year and they will want to cash in their chips as their bonuses depend on the very obvious. A lot on here enjoy sit and pray approach (aka buy and hold). Live and let live - that's what makes a market innit.
tongosti
25/11/2020
11:27
So, and in short, Covid-19 testing volumes will remain high through December, which supports/aligns with EKF's Trading Update. But it is noted that SBI refer to a 'possible' impact of Q1 testing volumes from the contract delay, which is subject to change while the UK government makes up its mind what it is doing, despite widely publicising it is massively expanding the availability and deployment of testing! Time will tell which way things move in this regard, but the overall impression is for a significant increase in testing demand, even with the roll out of vaccines. (but to be fair, when during the pandemic has anything the UK government said actually come to pass? Not to mention Randox being awarded a large UK contract for what looks like a shabby operation!). Growth in European test sales has not specifically featured either, which has always nagged me somewhat. The market appears to be applying the same logic with regard to US testing, which to my mind offers a different dynamic in terms of the current unfortunate and unprecedented surge in infections and testing volumes compared to UK testing, which has been somewhat shambolic, and that's being polite! Even with the well flagged massive expansion in global rapid antigen testing, the markets opinion is that it's possibly an opportunity missed. Time will tell, but I too note the FDA delays/backlog etc (could it be CE Marked?). The same with Antibody testing, the market is not factoring in much for this either (Possibly because Thermo won a large UK contract?). And despite such testing being widely recognised as important as vaccines are rolled out. Are we simply between a rock and a hard place, in terms of knowing exactly where PCR testing is going and unable to benefit from the huge surge in antigen testing (at this stage)? With neither the potential spin-out of Trellus, nor the CEO comment regarding the the share price overreaction, nor Source Bio's forecast EBITDA and the subsequent EV/EBITDA multiple providing enough to turn the markets view. Perhaps then we also need to tone down our expectations and expect less in terms of covid-19 testing revenues? However, EKF is an excellent business with an excellent management team, and with very bright future prospects, and thus it will remain a core long-term holding for me (I have not sold any shares).
wan
25/11/2020
11:06
Average crowd member has an entry price of £5.7 ytd (this is the average price for 2020). That means that the current paper profit (not cash in bank mind you) of our dear friend Joe amounts to about +5%. Over to you Senor Marcado ...
tongosti
25/11/2020
10:35
Some of us are forgetful... https://www.ekfdiagnostics.com/res/EKF%20UK%20COVID-19%20sample%20collection%20contract%2029.04.20.pdf https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/uk-contract-for-covid-19-sample-collection-kits/202004290700042370L/
mirandaj
25/11/2020
09:14
Surprised how no one has highlighted the RNS announcement from Source Bio today! Wed, 25th Nov 2020 07:00 RNS Number : 4087G SourceBio International PLC 25 November 2020 SourceBio International plc ("SourceBio", the "Company" or the "Group") Update on key COVID-19 testing contracts, capacity & Trading Update SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products, provides the following update on its testing contracts, its capacity for COVID-19 antigen RT-PCR testing services and an update on trading for its current financial year, ending 31 December 2020. Highlights · Renewal of testing services contract with Spire Healthcare Limited ("Spire") · Over 330,000 COVID-19 tests provided under existing Department of Health and Social Care ("DHSC") contract · Public Health England's ("PHE") National Microbiology Framework now expected to be awarded to successful applicants from February 2021 · SourceBio continues to build capacity for COVID-19 testing services to support expected further demand into 2021 · Application for National Microbiology Framework has been submitted on the basis of building testing volume capacity above management's earlier expectation of 10,500 tests per day · Award of NHS England framework for cancer testing services · The Group now expects to report revenue of approximately £50.0m (2019: £21.2m) and EBITDA of approximately £14.0m (2019: £3.0m) for the year ending 31 December 2020 Since May 2020, SourceBio has provided COVID-19 testing services as part of its newly formed Infectious Disease Testing business unit. These services passed all of the auditing requirements of the NHS and the DHSC in April 2020. Two key customers for the Company's COVID-19 testing services are the DHSC, under which SourceBio has been contracted to contribute to the critical national COVID-19 testing requirement, and the private healthcare group, Spire. The Spire contract was renewed in early November, as expected, and under the DHSC contract, which is set to expire on 12 December 2020, the Company has successfully processed over 330,000 COVID-19 PCR antigen tests. The DHSC contract is expected to be extended through Public Health England's ("PHE") National Microbiology Framework Lot 4 - Clinical Laboratory Diagnostic Testing Services ("Lot4"), however this framework is now not expected to be awarded until February 2021, although this may be subject to further change, having originally been expected to be awarded in November 2020. This delay is expected to impact testing volumes into Q1 2021 but the Board remains confident in its financial outlook for FY21 as a whole. Following the Company's Admission to AIM in October 2020, funds have underpinned further scale-up plans for COVID-19 testing and as a result the Company has submitted an updated Lot 4 application based on Directors' assumption of increased testing capacity beyond their original target of 10,500 tests per day. The Directors believe that the Company is well placed to bid for this framework given its capability, track record and high level of accreditation. In addition, the Company announces that it has been accepted into the Increasing Capacity Framework Agreement for cancer testing services to NHS England. This Framework is designed to reduce the significant backlog of elective surgeries impacting the NHS due to the COVID pandemic and is expected to support the continued growth of the Healthcare Diagnostics business unit in 2021. Due to the considerable ramp-up in COVID-19 testing revenues delivered in the second half of the year SourceBio expects to report total revenue of approximately £50.0m (2019: £21.2m) and EBITDA of approximately £14.0m (2019: £3.0m) for the year ending 31 December 2020, with the vast majority of this increase in expected earnings driven by the contribution of COVID-19 testing revenues. Jay LeCoque, Executive Chairman, said: "A key part of our investment case has always been our positioning to deliver against an unprecedented COVID-19 testing opportunity. The funds from our IPO are enabling us to further scale our COVID-19 testing services, to successfully deliver against expected increases in future testing. We believe we are in a very strong position for the Lot4 bid, and when awards are made in the New Year we have the potential to increase our testing volumes over the course of this framework." hTTps://sourcebiointernational.com/update-on-key-covid-19-testing-contracts-capacity-trading-update/ Source Bio shares up (slightly).
wan
25/11/2020
09:04
Can one please one remind us how much unlocked value is assigned to Trellus? LOLIf we close below 58 then 46 is the next immediate target. Don't blame me fellas - blame Mr Market!
tongosti
25/11/2020
08:25
The new Longhorn website provides a better insight to other testing capabilities and opportunities beyond Covid-19. But I also note that analysts in the US are starting to pencil in durable Covid-19 testing revenues in perpetuity post-pandemic, albeit at a reduced level to current revenues. It will then thus be interesting to see what effect this has in the availability of 'other' sample collection devices authorised under EUA that will no longer be authorised when the state of emergency is no longer in place. I would also add that Covid-19 testing revenues in the US are forecast to increase significantly due to the current and unprecedented surge in Covid-19 cases, and sadly that the subsequent demand is being seen as extending well into the first half of 2021.
wan
25/11/2020
07:59
Btgman...You may be right. Royal Mails postal collection contract has be running for a number of months already, so this latest contract news is an extension/expansion. I note that on EKF's postal kit web page it states "coming soon", so it would appear to imply that the kit was not available for the contract previously (so not included in previous Trading Updates?), or even if it's available now! So, arguably any such orders might not have been included in the recent upgrade. Recall that last month EKF highlighted that it materially increased its manufacturing capability/capacity, which at the very least implies durable demand - The Company has now started production at its facilities in Barleben, Germany, and will soon be moving its current Penarth-based manufacturing lines in Wales to a new larger facility in Llandough, Cardiff, which is over 600 sq. metres in size. This represents a 100% increase in manufacturing area.
wan
25/11/2020
07:21
Thanks wan absolutely fascinating. One thing I would say given the Royal Mail numbers I doubt there was very much in the last upgrade if anything at all. It would be good to get some clarity from EKF AIMHO GLA BTG
btgman
25/11/2020
07:07
Mirandaj...Yes, as I said the similarity is no guarantee, and the display of the logo can be used in different ways to comply - hTTps://www.simplexhealth.co.uk/covid19-coronavirus-pcr-swab-home-test-kit-p-1027.html
wan
25/11/2020
06:53
Wan I'm glad you posted that as I saw the Royal Mail kit box last night and did wonder. It looks the same to me although it says this so looks to be a standard: UN3373 postal box with security seal for sample return Sample transport box for mailing of category B biological samples to UN3373 P650 packaging standards. https://www.un3373.com/un3373-packaging/p650-packaging-instruction/
mirandaj
25/11/2020
06:47
Re postal testing kits: The following shows a photograph and a video, presumably of the actual postal kit- hTTps://www.royalmail.com/priority-postboxes I also note the following question - How safe is it for postmen and women? Is there a risk they will get infected? The health of our colleagues is our first priority. Royal Mail has worked in partnership with the Chief Medical Officer to ensure that the process is safe for our colleagues. The following also shows photographs of EKF's postal kit - hTTps://www.ekfdiagnostics.com/primestore-mtm-kit.html The similarity is obviously no guarantee it's EKF's, but as I already suggested and indeed the Royal mail video tends to confirm, the Royal Mail does not operate cold chain logistics. It may be that any postal supply contract was already contained within the Trading Update for the full year, but one assumes it could still increase.
wan
25/11/2020
06:11
Longhorn Vaccines & Diagnostics new website (so much better!) - hTTps://lhnvd.com/ I note that for the ATM product Longhorn is accepting orders for research use only, which perhaps fits with CEO's comment that some has been sold in the US, but with Thermo Fisher's marketing stating the availability of the product due to recent demand, also suggesting that there is already strong underlying interest in the attributes of ATM. Clearly, the FDA EUA (filed early September) will be an important factor in terms of large volume sales.
wan
Chat Pages: Latest  110  109  108  107  106  105  104  103  102  101  100  99  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210124 16:55:44